Erratum: A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer(British Journal of Cancer (2015) 112 (1215-1222) 10.1038/bjc.2015.81);A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer

British Journal of Cancer

Volumn 112, Issue 7, 2015, Pages 1215-1222

  Koti, M ^a   Siu, A ^a   Clement I ^b,c   Bidarimath, M ^a   Turashvili, G ^d   Edwards, A ^a   Rahimi, K ^e   Masson, A M M ^b,c   Squire, J A ^f  

^a QUEEN S UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c Institut du Cancer de Montreal   (Canada)

^d KINGSTON GENERAL HOSPITAL   (Canada)

^e CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^f UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chemoresistance; Ovarian cancer; Predictive biomarker; Tumour microenvironment

Indexed keywords

CFL1 PROTEIN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; FOCAL ADHESION KINASE 1; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HOST FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAP3K7 PROTEIN; MKNK1 PROTEIN; MONOCYTE CHEMOTACTIC PROTEIN 2; MYELOID DIFFERENTIATION FACTOR 88; RIPK1 PROTEIN; STAT1 PROTEIN; UNCLASSIFIED DRUG; STAT1 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIGH GRADE SEROUS EPITHELIAL OVARIAN CANCER; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MIDDLE AGED; OVARY CARCINOMA; PHENOTYPIC VARIATION; PRIMARY TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TISSUE MICROARRAY; TREATMENT RESPONSE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOUR INFLAMMATORY MICROENVIRONMENT; AGED; BIOSYNTHESIS; CANCER GRADING; COHORT ANALYSIS; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE; GENETICS; METABOLISM; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PATHOLOGY; PROGNOSIS; SURVIVAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; CYSTADENOCARCINOMA, SEROUS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; MIDDLE AGED; NEOPLASM GRADING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; STAT1 TRANSCRIPTION FACTOR; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MICROENVIRONMENT;

EID: 84938556627     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.459     Document Type: Erratum

References (43)

1. Ascierto ML, Kmieciak M, Idowu MO, Manjili R, Zhao Y, Grimes M, Dumur C, Wang E, Ramakrishnan V, Wang XY, Bear HD, Marincola FM, Manjili MH (2012) A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 131: 871-880.
2. Baxevanis CN, Papamichail M, Perez SA (2013) Immune classification of colorectal cancer patients: impressive but how complete? Expert Opin Biol Ther 13: 517-526.
3. Bernardini M, Lee CH, Beheshti B, Prasad M, Albert M, Marrano P, Begley H, Shaw P, Covens A, Murphy J, Rosen B, Minkin S, Squire JA, Macgregor PF (2005) High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. Neoplasia 7: 603-613.
4. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, Bruneval P, Fridman WH, Becker C, Pages F, Speicher MR, Trajanoski Z, Galon J (2013) Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 39: 782-795.
5. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA (2014) Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res 24: 743-750.
6. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
7. George PM, Badiger R, Alazawi W, Foster GR, Mitchell JA (2012) Pharmacology and therapeutic potential of interferons. Pharmacol Ther 135: 44-53.
8. Groom JR, Luster AD (2011) CXCR3 in T cell function. Exp Cell Res 317: 620-631.
9. Groom JR, Richmond J, Murooka TT, Sorensen EW, Sung JH, Bankert K, von Andrian UH, Moon JJ, Mempel TR, Luster AD (2012) CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4\+ T helper 1 cell differentiation. Immunity 37: 1091-1103.
10. Junttila MR, de Sauvage FJ (2013) Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 501: 346-354.
11. Klover PJ, Muller WJ, Robinson GW, Pfeiffer RM, Yamaji D, Hennighausen L (2010) Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden. Neoplasia 12: 899-905.
12. Koromilas AE, Sexl V (2013) The tumor suppressor function of STAT1 in breast cancer. JAKSTAT 2: e23353.
13. Koti M, Gooding RJ, Nuin P, Haslehurst A, Crane C, Weberpals J, Childs T, Bryson P, Dharsee M, Evans K, Feilotter HE, Park PC, Squire JA (2013) Identification of the IGF1/PI3K/NFkB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer. BMC Cancer 13: 549.
14. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R, Zou W (2009) Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149.
15. Kunz M, Toksoy A, Goebeler M, Engelhardt E, Brocker E, Gillitzer R (1999) Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J Pathol 189: 552-558.
16. Leitner NR, Lassnig C, Rom R, Heider S, Bago-Horvath Z, Eferl R, Muller S, Kolbe T, Kenner L, Rulicke T, Strobl B, Muller M (2014) Inducible, dose-adjustable and time-restricted reconstitution of STAT1 deficiency in vivo. PLoS One 9: e86608.
17. Levy DE, Gilliland DG (2000) Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice. Oncogene 19: 2505-2510.
18. Liu J, Matulonis U (2006) Rational use of cytotoxic chemotherapy for recurrent ovarian cancer. J Natl Compr Canc Netw 4: 947-953.
19. Marcus CS, Maxwell GL, Darcy KM, Hamilton CA, McGuire WP (2014) Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer 5: 25-30.
20. Martin JW, Chilton-MacNeill S, Koti M, van Wijnen AJ, Squire JA, Zielenska M (2014) Digital expression profiling identifies RUNX2, CDC5L, MDM2, RECQL4, and CDK4 as potential predictive biomarkers for neo-adjuvant chemotherapy response in paediatric osteosarcoma. PLoS One 9: e95843.
21. Milne K, Kobel M, Kalloger SE, Barnes RO, Gao D, Gilks CB, Watson PH, Nelson BH (2009) Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factors. PLoS One 4: e6412.
22. Muthuswamy R, Berk E, Junecko BF, Zeh HJ, Zureikat AH, Normolle D, Luong TM, Reinhart TA, Bartlett DL, Kalinski P (2012) NF-kappaB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res 72: 3735-3743.
23. Nelson BH (2010) CD20 \+ B cells: the other tumor-infiltrating lymphocytes. J Immunol 185: 4977-4982.
24. Ohtani H, Jin Z, Takegawa S, Nakayama T, Yoshie O (2009) Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3\+ T cells in lymphocyte-rich gastric carcinoma. J Pathol 217: 21-31.
25. Park YT, Jeong JY, Lee MJ, Kim KI, Kim TH, Kwon YD, Lee C, Kim OJ, An HJ (2013) MicroRNAs overexpressed in ovarian ALDH1-positive cells are associated with chemoresistance. J Ovarian Res 6: 18-2215-6-18.
26. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL (2013) The ratios of CD8(\+) T cells to CD4(\+)CD25(\+) FOXP3(\+) and FOXP3(-) T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One 8: e80063.
27. Rainczuk A, Rao J, Gathercole J, Stephens AN (2012) The emerging role of CXC chemokines in epithelial ovarian cancer. Reproduction 144: 303-317.
28. Raven JF, Williams V, Wang S, Tremblay ML, Muller WJ, Durbin JE, Koromilas AE (2011) Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation. Cell Cycle 10: 794-804.
29. Saha B, Jyothi Prasanna S, Chandrasekar B, Nandi D (2010) Gene modulation and immunoregulatory roles of interferon gamma. Cytokine 50: 1-14.
30. Sakamoto M, Kondo A, Kawasaki K, Goto T, Sakamoto H, Miyake K, Koyamatsu Y, Akiya T, Iwabuchi H, Muroya T, Ochiai K, Tanaka T, Kikuchi Y, Tenjin Y (2001) Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 14: 305-315.
31. Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101-1108.
32. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331: 1565-1570.
33. Selvanayagam ZE, Cheung TH, Wei N, Vittal R, Lo KW, Yeo W, Kita T, Ravatn R, Chung TK, Wong YF, Chin KV (2004) Prediction of chemotherapeutic response in ovarian cancer with DNA microarray expression profiling. Cancer Genet Cytogenet 154: 63-66.
34. Simpson JA, Al-Attar A, Watson NF, Scholefield JH, Ilyas M, Durrant LG (2010) Intratumoral T cell infiltration, MHC class I and STAT1 as biomarkers of good prognosis in colorectal cancer. Gut 59: 926-933.
35. Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Remedios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, Tuting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Preville X, Uze G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, Andre F, Kroemer G, Zitvogel L (2014) Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 20: 1301-1309.
36. Spivey TL, Uccellini L, Ascierto ML, Zoppoli G, De Giorgi V, Delogu LG, Engle AM, Thomas JM, Wang E, Marincola FM, Bedognetti D (2011) Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 9: 174-5876-9-174.
37. Sun Y, Yang S, Sun N, Chen J (2014) Differential expression of STAT1 and p21 proteins predicts pancreatic cancer progression and prognosis. Pancreas 43: 619-623.
38. Tymoszuk P, Charoentong P, Hackl H, Spilka R, Muller-Holzner E, Trajanoski Z, Obrist P, Revillion F, Peyrat JP, Fiegl H, Doppler W (2014) High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer. BMC Cancer 14: 257-2407-14-257.
39. Wang ZC, Birkbak NJ, Culhane AC, Drapkin R, Fatima A, Tian R, Schwede M, Alsop K, Daniels KE, Piao H, Liu J, Etemadmoghadam D, Miron A, Salvesen HB, Mitchell G, DeFazio A, Quackenbush J, Berkowitz RS, Iglehart JD, Bowtell DD. Australian Ovarian Cancer Study GroupMatulonis UA (2012) Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome. Clin Cancer Res 18: 5806-5815.
40. Weberpals JI, Koti M, Squire JA (2011) Targeting genetic and epigenetic alterations in the treatment of serous ovarian cancer. Cancer Genet 204: 525-535.
41. Yoshida S, Arakawa F, Higuchi F, Ishibashi Y, Goto M, Sugita Y, Nomura Y, Niino D, Shimizu K, Aoki R, Hashikawa K, Kimura Y, Yasuda K, Tashiro K, Kuhara S, Nagata K, Ohshima K (2012) Gene expression analysis of rheumatoid arthritis synovial lining regions by cDNA microarray combined with laser microdissection: up-regulation of inflammation-associated STAT1, IRF1, CXCL9, CXCL10, and CCL5. Scand J Rheumatol 41: 170-179.
42. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH (2008) Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 48: 1440-1450.
43. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN, Rubin SC, Coukos G (2003) Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348: 203-213.